Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Gilead discontinues gastric cancer candidate andecaliximab

November 2, 2018 7:49 PM UTC

Gilead Sciences Inc. (NASDAQ:GILD) announced in its 3Q18 earnings that it discontinued development of andecaliximab for gastric cancer. The company said a Phase III trial showed a lack of benefit on ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Gilead Sciences Inc.